Overview

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes need for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving celecoxib together with docetaxel or pemetrexed may kill more tumor cells. PURPOSE: This phase II trial is studying how well celecoxib given together with docetaxel or pemetrexed works in treating patients with advanced or recurrent non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Celecoxib
Docetaxel
Pemetrexed